Claritas NucMed Technologies, a firm engaged in image processing, lesion detection, and quantification for the nuclear medicine sector, has completed all regulatory requirements to set up its new Brazilian subsidiary.
Claritas NucMed Tech Brazil will be headquartered in São Paulo, Brazil.
The expansion is expected to allow Claritas NucMed Technologies, a subsidiary of UK-based Claritas HealthTech, to enhance its global presence.
Claritas NucMed’s software device will address challenges within Brazil’s nuclear medicine sector including environmental impacts, high costs, and limited access to services.
Claritas NucMed Tech Brazil will use its wholly owned subsidiary, New Vida Medicamentos e Produtos, an approved distributor of medical devices in Brazil, for the expansion.
The partnership will advance the deployment and clinical collaboration of its software suite for positron emission tomography (PET) and single photon emission computed tomography (SPECT) with medical institutions throughout the country.
The registration process for Claritas NucMed software products is underway with ANVISA (Agência Nacional de Vigilância Sanitária), Brazil’s medical device regulatory authority.
Claritas NucMed Tech Brazil is registering products used for accelerated and reduced isotope scans and automated lesion detection.
Claritas NucMed Tech Brazil managing director Fernando Salis said: “In terms of the number of PET-CT scans alone, the current estimated number stands at about 20,000 per month, up from only 1,800 per month 10 years ago.”
“Despite growth rates that are estimated at 7% per year, there are shortages with demand outstripping supply due to the long scanning time and the challenges of high cost, short life and transportation issues of the isotopes.
“This is the perfect time for the introduction of solutions from Claritas NucMed which could help to improve efficiencies, reduce costs and provide patient benefits.”
Claritas NucMed distributes Claritas iPET, iPETcertum, iSPECTcardiac, and other nuclear medicine devices internationally.
The nuclear medicine company was separated from Claritas HealthTech in July this year.
In the same month, Claritas HealthTech secured clearance from India’s Central Drugs Standard Control Organisation (CDSCO), for importing and marketing the Claritas iPET software in India.
